SCHEMBL8202723

SCHEMBL8202723

Clc1ccc(-c2ccccc2C2=NCCN2)cc1

nearest known ligand 0.75

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ NISCH Q9Y2I1 8/20 0.75
▸ LMNA P02545 1/20 0.67
▸ RECQL P46063 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8194068 0.85 NISCH (0.77) NISCH
SCHEMBL9579892 0.84 NISCH (0.81) NISCH
SCHEMBL8197935 0.83 NISCH (0.75) NISCH
SCHEMBL8195009 0.82 NISCH (0.74) NISCHLMNARECQL
SCHEMBL523059 0.82 LMNA (0.96) NISCHLMNARECQL
SCHEMBL8188355 0.80 LMNA (0.92) NISCHLMNARECQL
SCHEMBL8202988 0.80 NISCH (0.71) NISCH
SCHEMBL8200536 0.80 NISCH (0.71) NISCH
SCHEMBL8189633 0.80 NISCH (0.71) NISCH
SCHEMBL8239326 0.80 NISCH (0.57) NISCHLMNARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2000078726-A1 IMIDAZOLINE DERIVATIVES FOR THE TREATMENT OF DIABETES, ESPECIALLY TYPE II DIABETES ELI LILLY AND COMPANY (US) 2000-12-28 — — WO disclosed
Send feedback